

## **TEST CHANGE**

Paliperidone, Serum or Plasma	3
2007949, PALIPERID	
Specimen Requirements:	
Patient Preparation:	Pre-dose (trough) draw - At steady state concentration.
Collect:	Plain Red. Also acceptable: Lavender (EDTA) or Pink (K2EDTA).
Specimen Preparation:	Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Transport Temperature:	Refrigerated.
Unacceptable Conditions:	Whole blood. Gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution).
Remarks:	
Stability:	Ambient: 2 weeks; Refrigerated: 2 weeks; Frozen: 2 months
Methodology:	Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Performed:	Wed, Sat
Reported:	1- <u>8</u> 5 days
Note:	
CPT Codes:	80342 (Alt code: G0480)
New York DOH Approval Status:	This test is New York DOH approved.
Interpretive Deter	

Interpretive Data:

The therapeutic range is based on serum pre-dose (trough) draw at steady-state concentration. Adverse effects to paliperidone therapy may include headache, nausea, dizziness, tachycardia, orthostatic hypotension and dyskinesia.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Reference Interval:



## Effective June 7, 2021

Therapeutic range (Paliperidone (9- hydroxyrisperidone))	20 - 60 ng/mL
Toxic range (Paliperidone (9- hydroxyrisperidone))	Greater than 120 ng/mL